UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  October 25, 2016

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
 
000-50761
 
11-3146460
 
(State or Other Jurisdiction of Incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)
 
14 Plaza Drive, Latham, New York      12110
(Address of Principal Executive Offices)                 (Zip Code)

(518) 798-1215
(Registrant’s telephone number, including area code)
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
Item 5.07 – Submission of Matters to a Vote of Security Holders.

(a)
The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on October 25, 2016.

(b)
Shareholders voted on the matters set forth below.

1.
The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2019 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:

Nominee
  
Votes For
  
Withheld
  
Broker Non Votes
             
Jeffrey G. Gold
  
28,128,285
  
2,230,302
  
0
             
Kevin J. Gould
  
28,953,931
  
1,404,656
  
0
             
Dennis S. Meteny
  
27,473,650
  
2,884,937
  
0

2.
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:

Votes for approval
29,969,567
Votes against
384,112
Abstentions
4,908
Broker non votes
0

3.
The proposal to amend the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan was approved based upon the following votes:

Votes for approval
26,692,947
Votes against
3,651,366
Abstentions
14,274
Broker non votes
0

 
 
 
 
4.
The proposal to amend the AngioDynamics, Inc. Employee Stock Purchase Plan was approved based upon the following votes:

Votes for approval
30,267,524
Votes against
75,335
Abstentions
15,728
Broker non votes
0





(c)
Not applicable.

(d)
Not applicable.




SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ANGIODYNAMICS, INC.
(Registrant)
  
       
Date: October 28, 2016
By:
/s/ Stephen A. Trowbridge  
    Stephen A. Trowbridge  
    Senior Vice President and General Counsel